Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

1. Hurvitz, S.A.
2. Hegg, R.
3. Chung, W.-P.
4. Im, S.-A.
5. Jacot, W.
6. Ganju, V.
7. Chiu, J.W.Y.
8. Xu, B.
9. Hamilton, E.
10. Madhusudan, S.
11. Iwata, H.
12. Altintas, S.
13. Henning, J.-W.
14. Curigliano, G.
15. Perez-Garcia, J.M.
16. Kim, S.-B.
17. Petry, V.
18. Huang, C.-S.
19. Li, W.
20. Frenel, J.-S.
21. Antolin, S.
22. Yeo, W.
23. Bianchini, G.
24. Loi, S.
25. Tsurutani, J.
26. Egorov, A.
27. Liu, Y.
28. Cathcart, J.
29. Ashfaque, S.
30. Cortés, J.
31. Show all authors +

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1016/S0140-6736(22)02420-5 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus